The biliary elimination of mezlocillin, a new semisynthetic penicillin of the acyl-ureido-penicillin group, was investigated in vitro in rabbit liver preparations and in vivo in humans. Experimentally, mezlocillin recovery in the bile during perfusion of isolated rabbit liver (3 h; n = 5) averaged 20.3% of the administered dose (10 mg). The mean peak concentration in the bile (758 ± 129.3 ,ug/ml) was reached between 0.5 and 1 h. Biliary clearance was 169 ml/h. In healthy subjects (n = 5), the concentrations of antibiotic measured in the duodenal fluid during a period of 4 h after intravenous administration of 5 g of mezlocillin ranged between 440 and 637 ,ug/ml. In 10 cholecystectomized patients provided with a T-tube, intramuscular injection of 1 g of mezlocillin resulted in a biliary peak concentration of 295.7 ± 58.1 ,ug/ml. Mean total amount of antibiotic eliminated in the bile over 12 h corresponded to 2.6% of the administered dose. Assays performed during surgery after intravenous administration of 2 g of mezlocillin (n = 10) showed antibiotic activity of 895 ± 196 ,ug/ml in the common duct bile and 402 ± 133 ytg/ ml in the gallbladder bile. These data were compared with the values determined for 11 other beta-lactamines studied under identical conditions.
The biliary elimination of mezlocillin, a new semisynthetic penicillin of the acyl-ureido-penicillin group, was investigated in vitro in rabbit liver preparations and in vivo in humans. Experimentally, mezlocillin recovery in the bile during perfusion of isolated rabbit liver (3 h; n = 5) averaged 20.3% of the administered dose (10 mg). The mean peak concentration in the bile (758 ± 129.3 ,ug/ml) was reached between 0.5 and 1 h. Biliary clearance was 169 ml/h. In healthy subjects (n = 5), the concentrations of antibiotic measured in the duodenal fluid during a period of 4 h after intravenous administration of 5 g of mezlocillin ranged between 440 and 637 ,ug/ml. In 10 cholecystectomized patients provided with a T-tube, intramuscular injection of 1 g of mezlocillin resulted in a biliary peak concentration of 295.7 ± 58.1 ,ug/ml. Mean total amount of antibiotic eliminated in the bile over 12 h corresponded to 2.6% of the administered dose. Assays performed during surgery after intravenous administration of 2 g of mezlocillin (n = 10) showed antibiotic activity of 895 ± 196 ,ug/ml in the common duct bile and 402 ± 133 ytg/ ml in the gallbladder bile. These data were compared with the values determined for 11 other beta-lactamines studied under identical conditions.
Mezlocillin is a new semisynthetic penicillin of the acyl-ureido-penicillin group; it is characterized by a wide spectrum of activity (1) including particularly Enterococcus, Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides. Since these microorganisms are frequently encountered in biliary.infections (5) , it appeared especially useful to determine the concentrations that this antibiotic attains in the biliary tree.
The purpose of this work was to evaluate biliary elimination of mezlocillin in isolated rabbit liver and in humans. The latter group included healthy subjects submitted to duodenal intubation, cholecystectomized patients with Ttube drainage, and patients undergoing cholecystectomy allowing bile sampling in the common duct and the gallbladder.
These investigations were part of a more general comparative study of biliary elimination of the beta-lactamines (2, 3) .
MATERIALS AND METHODS
Perfusion of isolated rabbit liver. Five isolated rabbit liver preparations (mean liver weight, 78.0 ± 7.2 g) were perfused for 3.5 h in a closed circuit, with reconstituted, heparinized, defibrinated, and oxygenated blood, according to a technique previously described (2) . Throughout these experiments, bile was collected by means of a catheter inserted into the common bile duct.
Ten milligrams of mezlocillin was added to the circulating blood at the end of the first 30 min of perfusion. Antibiotic activity was assayed in serum samples taken at 30-min intervals and in bile specimens collected over 30-min periods. The amount of mezlocillin in the liver was determined in hepatic fragments obtained at the end of the perfusion.
Clinical investigation: patient selection and procedure. Ten recently cholecystectomized patients with T-tube drainage and no evidence of kidney and liver impairment were studied after intramuscular injection of a single 1-g dose of mezlocillin. Concentrations of the antibiotic were measured in serum samples taken at hourly intervals for 12 h and in hourly bile specimens collected for 12 h. These examinations were usually performed on postoperative day 8, a time that was sufficiently remote from the surgical procedure but a time at which the biliary flow via the Kehr's drain was still marked.
Five healthy subjects with normal hepatic function were given 5 g of mezlocillin by intravenous (i.v.) infusion over a 30-min period after insertion of a duodenal tube. Antibiotic levels in serum were determined at hourly intervals, and antibiotic activity in duodenal fluid was measured in hourly samples collected for 4 successive hours.
In 10 patients undergoing cholecystectomy for gallstones (without obstruction of the main bile duct; see 
RESULTS
Perfusion of isolated rabbit liver (Table  1 ). After addition of 10 mg of mezlocillin to the circulating blood, the mean serum concentration decreased progressively from an initial theoretical value of 11.8 to 0.7 jig/ml at the end of the The mean biliary concentration reached a maximum between 0.5 and 1 h (758.0 ± 129.3 ,ig/ml). Total antibiotic recovery from the bile in the 3 h after addition of mezlocillin averaged 2,027 ± 482 ,ug, i.e., 20.3% of the administered dose. Calculated by formulas previously described (3), the biliary clearance, Cb, was found to be 169 ml/h (2.2 ml/h per g of liver), and the coefficient of biliary elimination, Kb, was 0.1995 h-i; at the end of the perfusion, the mean amount of mezlocillin still present in the liver was 62.4 jig (0.8 jig per g of liver).
Control experiments showed that over a period of 3 h after addition of 10 mg of mezlocillin to 300 ml of reconstituted blood, serum antibiotic activity decreased by 12.1% after storage at 37°C, by 17.1% after addition of 100 mg of heparin and storage at 37°C, and by 21.0% after addition of 100 mg of heparin and simple circulation (with oxygenation) in a liver-free perfusion system.
Elimination of mezlocillin in humans ( Table 2 ). (i) Levels of mezlocillin in fluid aspirated from the duodenum in normal subjects. Considerable amounts of mezlocillin were found in the duodenal fluid; the ratio duodenal fluid antibiotic activity/serum antibiotic activity rose throughout the examination from h-').
(iii) Intraoperative samplings (Table 4 ). The antibiotic activities measured in the gallbladder and common duct bile 1 h after i.v. injection of 2 g of mezlocillin were, on average, 14 and 31 times greater, respectively, than the serum concentration determined simultaneously. DISCUSSION Few experimental data concerning the biliary elimination of mezlocillin are available. In rats, the Nippon University group (6) observed biliary concentrations in excess of 2,000 ,ug/ml after i.v.
injection of 20 mg of mezlocillin per kg (n = 3). Also in rats, Gundert-Remy et al. (4) showed that experimental cholestasis considerably reduces the biliary elimination of mezlocillin. In rabbits, the Hiroshima University group (6) reported bile levels above 1,000,ug/ml after intravenous (n = 3) or intraduodenal (n = 3) administration of 50 mg of mezlocillin per kg. The biliary peaks (mean = 758 ,ug/ml) measured during our perfusions of isolated rabbit liver were not as high, but a lower dose of mezlocillin was used (26 mg/kg).
Our experimental studies indicate that, in addition to degradation due to the prolonged exposure of mezlocillin to blood medium at 37°C (12%), a further decrease in the antibiotic activity was produced by heparin (5%) and by the perfusion device itself (4%) (binding and degradation on the wall and the catheters of the perfusion apparatus; oxidation in the oxygenator).
Taking into account the amount of mezlocillin eliminated in the bile (2,027 ,ug, or 20.3% of the administered dose) and the amount of antibiotic still present in the circulating blood (210 ,ug, or 2.1% of the administered dose) and in the liver (62.4 jig, or 0.62% of the administered dose) at the end of the perfusion, it would appear that 56% of the mezlocillin is inactivated or metabolized in the liver (Fig. 1) . The very low level of mezlocillin found in the liver at the end of perfusion also suggests that this antibiotic undergoes hepatic biotransformation.
It could be interesting to compare these data with those of our previous studies performed under identical conditions and concerned with the biliary elimination of 11 other beta-lactamines; under these conditions, the biliary elimination of mezlocillin exceeded that of all the other antibiotics investigated, except metampicillin (Fig. 2) .
In subjects with normal hepatic function (n = 6), Gundert-Remy et al. (4) reported that considerable amounts of mezlocillin are excreted in bile; according to these authors, 12 to 26% of the dose of antibiotic given i.v. is recovered in the bile collected from a T-tube during the 8 h after administration. These values are considerably lower (0.05 to 10.5%) in patients with severe hepatic disorders (n = 8). In a study carried out under similar conditions by the group at Hiroshima University (6) , the biliary elimination (0 to 8 h) corresponded to 7.5% of the dose of mezlocillin injected (2 g i.v.), and the biliary h FIG. 1 . Distribution of antibiotic activity after administration of mezlocillin during perfusion of isolated rabbit liver. Abbreviations: s, serum antibiotic activity at the end of the perfusion (2.1%); h, hepatic antibiotic activity at the end of the perfusion (0.6%); b, biliary excretion (20.3%); i, inactivation in the perfusion apparatus (21%); m, hepatic inactivation or biotransformation (56%). peak was 2,070 ,ug/ml. Using the same technique and identical doses (2 g i.v., n = 15, 0 to 6 h), the Nagoya City University group (6) obtained lower values: biliary elimination of 2.9 ± 0.5% and a maximum concentration in the bile of 482.5 ± 71.4 jig/ml. These results are in better agreement with our own findings; it should be noted that the mean bile volume of our patients provided with a T-tube during the examination was 200 ± 33 ml. Taking into account an individual's daily production of bile, which, on the 8th day after cholecystectomy, has been evaluated at 500 to 600 ml (7) , it can be estimated that the external bile drainage accounted for only about two-thirds of the bile secreted by the liver. Total biliary elimination of mezlocillin therefore would be at least 30% greater than our results suggest.
Mezlocillin levels observed during surgery, 1 h after injection of the antibiotic, were much higher in the common duct bile than in the gallbladder bile. This difference may be related to gallbladder disease (lithiasis, chronic cholecystitis) and cystic duct obstruction (Table 4) , which motivated the cholecystectomy. Even after adjustments for the dose differences, the intraoperative concentrations of mezlocillin so measured in the common duct bile of patients with a T-tube were much greater than those observed in the bile collected during the 1st and 2nd hours of examination. This discrepancy can probably be attributed to the dilution effect related to the length of the T-tube. Compared with the biliary elimination of 11 other beta-lactamines studied by the same procedure, the biliary passage of mezlocillin is less marked than that of metampicillin but much more marked than that of the 10 other antibiotics in this group (Fig. 2) .
From the data published in the literature (1-8), it appears that mezlocillin concentrations of 50 to 100 ,ug/ml are sufficient to inhibit the majority of microorganisms responsible of biliary infections, most of which are included in this antibiotic's spectrum of activity. As shown by the present study, these concentrations are exceeded in the bile during the 10 h after intramuscular injection of 1 g of mezlocillin. Considering mezlocillin's particularly valuable antimicrobial properties, these findings suggest that administration of this antibiotic is particularly suitable for the treatment of biliary tract infections. These preliminary experimental results must obviously be confirmed by clinical trials.
